TrialsgrambetaRCTs are beautiful

Captopril-DN

1993

Captopril in Diabetic Nephropathy (Collaborative Study Group)

In 409 patients with type 1 diabetes and diabetic nephropathy, captopril reduced doubling of serum creatinine compared with placebo.

Result

Efficacy: Doubling of baseline serum creatinineHR 0.52 (95% CI 0.31-0.84) · P = 0.007

Below 1 favours captopril, above 1 favours placebo.

Also reported: ~50% reduction in death, dialysis, or transplantation.

Original publication
Subtopic
RAAS blockade
Design
Double-blind RCT, median 3-year follow-up
Relevance
Practice-defining: a trial the guidelines cite as evidence.
Source
Lewis EJ, et al. N Engl J Med. 1993;329(20):1456-1462.doi 10.1056/NEJM199311113292004

Discussion & critique

First proof of renoprotection beyond blood-pressure lowering; established ACE inhibitors as standard in type 1 diabetic nephropathy. Limited to T1DM with no blood-pressure-equivalent control arm.

Discussed in podcasts